Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Bladder cancer
Stage/Subtype:  stage II bladder cancer
Country:  U.S.A.
Trial Type:  Treatment
Results 1-16 of 16 for your search:
Start Over
Transurethral Resection of Bladder Tumors Using PK Button Vaporization Electrode or Monopolar Loop Electrocautery in Treating Patients with Bladder Cancer
Status: Active
Phase: Phase IV
Type: Treatment
Age: 18 to 89
Trial IDs: WCI2119-11, NCI-2013-00065, IRB00053735, NCT01567462
A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection [IMvigor010]
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: WO29636, NCI-2015-01334, 2014-005603-25, NCT02450331
A Study to Evaluate INSTILADRIN® in Patients With High Grade, Bacillus Calmette-Guerin (BCG) Unresponsive NMIBC
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: rAd-IFN-CS-003, NCI-2016-01157, NCT02773849
Gemcitabine Hydrochloride and Cisplatin in Treating Patients with High-Grade Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 10-208, NCI-2010-02376, NCT01261728
Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1314, NCI-2014-00850, NCT02177695
Pembrolizumab, Gemcitabine Hydrochloride and Radiation Therapy in Treating Patients with Bladder Urothelial Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S15-00220, NCI-2016-00717, NCT02621151
Gemcitabine Hydrochloride, Cisplatin, and Pembrolizumab before Surgery in Treating Patients with Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: LCCC1520, NCI-2016-00790, NCT02690558
Nivolumab and Ipilimumab in Treating Patients with Rare Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S1609, NCI-2016-01041, NCT02834013
Nivolumab in Treating Patients with Stage II-IV Muscle-Invasive Bladder, Urethra, or Ureter Cancer That Have Undergone Chemoradiotherapy
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: HCI100769, NCI-2017-01197, CA209-999, NEXT, NCT03171025
Safety and Tolerability of GemRIS 225 mg in Subjects With Muscle-Invasive Bladder Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: TAR-200-101, NCI-2016-00507, NCT02722538
Durvalumab and Tremelimumab in Treating Patients with Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated with Cisplatin-Based Therapy before Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2016-0033, NCI-2016-01147, NCT02812420
PGV001 in Treating Patients with Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 15-1811, NCI-2017-01044, NCT02721043
MRI Before and During Surgery in Diagnosing Patients With Bladder Cancer
Status: Active
Phase: No phase specified
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: OSU-08063, NCI-2012-00937, 2009C0001, NCT00938145
Observation or Immediate Surgery in Reducing Complications in Patients with Low Risk Bladder Cancer
Status: Active
Phase: No phase specified
Type: Treatment
Age: 50 and over
Trial IDs: VICC URO 15139, NCI-2016-00677, NCT02700724
sEphB4-HSA before Surgery in Treating Patients with Bladder Cancer, Prostate Cancer, or Kidney Cancer
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 0S-15-6, NCI-2015-02236, NCT02767921
Start Over